Chen Hongjiang, Li Dayuan, Saldeen Tom, Mehta Jawahar L
Departments of Internal Medicine and Physiology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205-7199, USA.
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1612-7. doi: 10.1152/ajpheart.00992.2002.
Ischemia-reperfusion (I/R) is thought to upregulate the expression and activity of matrix metalloproteinases (MMPs), which regulate myocardial and vascular remodeling. Previous studies have shown that transforming growth factor-beta(1) (TGF-beta(1)) can attenuate myocardial injury induced by I/R. TGF-beta(1) is also reported to suppress the release of MMPs. To study the modulation of MMP-1 by TGF-beta(1) in I/R myocardium, Sprague-Dawley rats were given saline and subjected to 1 h of myocardial ischemia [total left coronary artery (LCA) ligation] followed by 1 h of reperfusion (n = 9). Parallel groups of rats were pretreated with recombinant TGF-beta(1) (rTGF-beta(1), 1 mg/rat, n = 9) before reperfusion or exposure to sham I/R (control group). I/R caused myocardial necrosis and dysfunction, indicated by decreased first derivative of left ventricular pressure, mean arterial blood pressure, and heart rate (all P < 0.01 vs. sham-operated control group). Simultaneously, I/R upregulated MMP-1 (P < 0.01). Treatment of rats with rTGF-beta(1) reduced the extent of myocardial necrosis and dysfunction despite I/R (all P < 0.01). rTGF-beta(1) treatment also inhibited the upregulation of MMP-1 in the I/R myocardium (P < 0.05). To determine the direct effect of MMP-1 on the myocardium, isolated adult rat myocytes were treated with active MMP-1, which caused injury and death of cultured myocytes, measured as lactate dehydrogenase release and trypan blue staining, in a dose- and time-dependent manner (P < 0.05). Pretreatment with PD-166793, a specific MMP inhibitor, attenuated myocardial injury and death induced by active MMP-1. The present study for the first time shows that MMP-1 can directly cause myocyte injury or death and that attenuation of myocardial I/R injury by TGF-beta(1) may, at least partly, be mediated by the inhibition of upregulation of MMP-1.
缺血再灌注(I/R)被认为可上调基质金属蛋白酶(MMPs)的表达和活性,而MMPs可调节心肌和血管重塑。既往研究表明,转化生长因子-β1(TGF-β1)可减轻I/R诱导的心肌损伤。也有报道称TGF-β1可抑制MMPs的释放。为研究TGF-β1对I/R心肌中MMP-1的调节作用,将Sprague-Dawley大鼠给予生理盐水,并使其经历1小时心肌缺血(完全结扎左冠状动脉),随后再灌注1小时(n = 9)。在再灌注或假I/R(对照组)之前,对平行组大鼠用重组TGF-β1(rTGF-β1,1mg/只,n = 9)进行预处理。I/R导致心肌坏死和功能障碍,表现为左心室压力一阶导数、平均动脉血压和心率降低(与假手术对照组相比,均P < 0.01)。同时,I/R上调了MMP-1(P < 0.01)。用rTGF-β1治疗大鼠可减轻I/R所致的心肌坏死程度和功能障碍(均P < 0.01)。rTGF-β1治疗还抑制了I/R心肌中MMP-1的上调(P < 0.05)。为确定MMP-1对心肌的直接作用,用活性MMP-1处理分离的成年大鼠心肌细胞,并以剂量和时间依赖性方式导致培养的心肌细胞损伤和死亡(以乳酸脱氢酶释放和台盼蓝染色衡量,P < 0.05)。用特异性MMP抑制剂PD-166793预处理可减轻活性MMP-1诱导的心肌损伤和死亡。本研究首次表明,MMP-1可直接导致心肌细胞损伤或死亡,且TGF-β1减轻心肌I/R损伤可能至少部分是通过抑制MMP-1上调介导的。